This educational podcast from ADVENT explores emerging approaches to early intervention and disease modification in atopic dermatitis management.

ATOPIC-DERMATITIS

Charting New Course: The Frontier of Early Intervention and Disease Modification in AD

This scientific podcast, part of the ADVENT on Air initiative, delves into the cutting-edge realm of early intervention and disease modification in atopic dermatitis (AD). 
 Key focus areas include: 
 1. The science of type 2 inflammation and its pivotal role in AD pathogenesis 
 2. In-depth exploration of atopic dermatitis pathophysiology 
 3. Emerging frontiers in early therapeutic interventions for AD 
 4. Current research and future prospects in disease modification strategies

Early Intervention and Disease Modification in Atopic Dermatitis

<h3>Key Points from the New PHA Recommendations</h3>
1. Benefits of Early Detection
The guideline emphasizes that early detection in high-risk populations enables proactive strategies that may prevent or delay the onset of T1DM, and significantly reduces the likelihood of diabetic ketoacidosis (DKA) at presentation.
Early detection in high-risk populations allows for proactive trials aiming to prevent or delay the onset of T1DM and to prevent diabetic ketoacidosis at presentation [76,77].
2. A Structured Framework for Prevention
The PHA outlines a 3-level prevention strategy for T1DM, aligned with international consensus:
Type 1 diabetes (T1DM) is a heterogeneous disease and progresses over different stages. Prevention of T1DM is an evolving field encompassing primary, secondary, and tertiary prevention strategies.&nbsp;
Primary Prevention: Efforts toward primary prevention aim to intervene before the onset of T1DM in individuals at risk. Genetic screening and identification of high-risk groups, such as first-degree relatives of individuals with T1DM, serve as key components. While current clinical guidelines recommend screening for at-risk individuals, achieving global universal screening remains a long-term goal [81].&nbsp;
Secondary Prevention: Secondary prevention focuses on delaying or preventing the progression of preclinical stages to overt diabetes. The identification of stages in T1DM progression, as outlined in recent International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines, provides a valuable framework for intervention [82]. Understanding the heterogeneity and endotypes in T1DM further refines secondary prevention approaches, allowing for targeted strategies [83].
Tertiary Prevention: […] the progress in preventing T1DM is complex, involving genetic screening, comprehension of disease progression stages, and the exploration of innovative interventions. Considering that 85% of T1DM patients lack a family history of the condition, the global focus on universal screening and continuous research initiatives is shaping the dynamic field of T1DM prevention.
Click the below button to see all information about Saudi Health Promotion and Prevention Guideline for Diabetes Mellitus

Saudi Health Promotion and Prevention Guideline for Diabetes Mellitus

TYPE-1-DIABETES

DIABETES

Access all the content and events you need to continue growing as a health professional.

Welcome To Campus Sanofi KSA

OUT-OF-TAXONOMY

To read the full content, activate your Sanofi Campus account. Please confirm your email address in the email you received.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

This information will only be used to validate your account and will not be distributed.

title

Before starting exploring, we can suggest you specific and relevant content

Title

This website is for healthcare professionals only

Welcome to BP Sanofi Campus

Create new password

To offer you a personalised experience, you must

Your profile is incomplete

The ADCT gives a measure of how controlled the eczema is. Answer these 6 simple questions with your patient to find the ADCT score. It will indicate proper course of action.

Atopic dermatitis, a type of eczema, may be affecting your Patient's life in more ways than you know.

Take the Atopic Dermatitis Control Test (ADCT)

Enjoy more exclusive content{newline}by <a>registering today</a>

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

This website is for healthcare professionals only.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

We're usually a treasure chest of knowledge, but we couldn't find what you're looking for.

We were unable to find what you're searching for

You are about to leave Campus.sanofi/uk.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch. All fields are required.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Are you enrolled in CENRIFKI REMS?

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your local Sanofi representative and/or to receive updates about Qfitlia. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required (unless otherwise specified).

All fields are required. (unless otherwise specified)

This site is intended for healthcare professionals only and contains information on Sanofi medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs.

Welcome to Sanofi Campus

Welcome to ITP Sanofi Campus

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privacy matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My consents

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please log in to access to the results

You need to sign-in to your account in order to access medical content.

Please Log In

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Welcome To Campus Sanofi KSA

Scientific News

Charting New Course: The Frontier of Early Intervention and Disease Modification in AD

Early Intervention and Disease Modification in Atopic Dermatitis

Saudi Health Promotion and Prevention Guideline for Diabetes Mellitus

Quick Links

Support for your patients

Payor